Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma

NCT07657143 | Not Yet Recruiting Phase 4

• 1 other identifier: 32885
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Trachoma is caused by repeated Chlamydia trachomatis infection in the eye. Routes of infection include close person-to-person contact and contaminated clothing. In addition, the bazaar fly Musca sorbens has been implicated in transmission. These flies frequently visit the faces of children and have been found positive for C. trachomatis, which may be transferred from the body of the flies or their regurgitated or defecated material. This study aims to give recruited healthy volunteers a safe dose of oral ivermectin. Their faeces will be collected over subsequent days to determine whether ivermectin excreted from the body results in faecal concentrations that are high enough to prevent emergence of M. sorbens developing in faeces. It will also quantify ivermectin concentrations in tears secretions and faecal samples for up to 30 days post-treatment.

Conditions

Survival of Flies Developing in Faecal Samples

Keywords

Trachoma; Ivermectin; Musca flies

Outcome Measures

Primary Outcomes (1)

• Musca sorbens larvae surviving to adulthood

  The difference in the mean number of Musca sorbens larvae surviving to adulthood in faecal samples collected at each post-treatment time point compared to pre-treatment samples. The treatment effect will be estimated separately at each time point.

  Days 1, 2, 3, 4, 5, 10 and 30 post treatment

Secondary Outcomes (4)

• Concentration of ivermectin in faeces

  Days 1, 2, 3, 4, 5, 10 and 30 post treatment

• First oviposition event

  Days 1, 2, 3, 4, 5, 10 and 30 post treatment

• Behvioural response

  Days 1, 2, 3, 4, 5, 10 and 30 post treatment

• Adult fly survival

  Each time pointDays 1, 2, 3, 4, 5, 10 and 30 post treatment

Study Arms (1)

Ivermectin treatment

EXPERIMENTAL

Participants to receive safe oral dose of ivermectin

Drug: Ivermectin

Interventions

Ivermectin DRUG

Oral dose of ivermectin (150 micrograms/kg)

Ivermectin treatment

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able and willing to give fully informed consent
• Able to understand and comply with the study procedures
• Able to produce a stool on most days
• Consider themselves to be in good general health
• Aged 18 to 65 years

You may not qualify if:

• Suspected or known to be sensitive or allergic to ivermectin
• Women who are pregnant, nursing or intending to become pregnant
• Aware of having any neurological disorders or recent history of seizures
• History of travel to a region endemic for Loa loa.
• Currently taking acenocoumarol, warfarin or levimasole

Sponsors & Collaborators

• London School of Hygiene and Tropical Medicine: lead

Study Sites (1)

London School of Hygiene & Tropical Medicine

London, WC1E 7HT, United Kingdom

Location

MeSH Terms

Conditions

Trachoma

Interventions

Ivermectin

Condition Hierarchy (Ancestors)

Conjunctivitis, Bacterial; Eye Infections, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Chlamydia Infections; Chlamydiaceae Infections; Gram-Negative Bacterial Infections; Eye Infections; Conjunctivitis; Conjunctival Diseases; Eye Diseases; Corneal Diseases

Intervention Hierarchy (Ancestors)

Macrolides; Polyketides; Lactones; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Masking Details: Investigators exposing flies to the faeces of volunteers will be masked as to the treatment (whether the sample is pre- or post-treatment).
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: All participants to be given a single doe of ivermectin.

Study Record Dates

• First Submitted: June 11, 2026
• First Posted: June 18, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: June 18, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)